IPC’s International Fellowship program offers early-career dermatologists and researchers interested in psoriasis the opportunity to learn directly from our global network of experts, demonstrating our commitment to developing the next generation of leaders in the field.
IPC offers two fellowship tracks: Clinical and Research. Both are 12-month programs that include virtual mentoring, skills development classes, and co-mentoring groups based on special interest topics. Clinical fellows will participate in up to four weeks of on-site clinical experience, while research fellows will spend up to twelve weeks on-site with a research mentor. Applicants may apply to one or both tracks through a single application.
The project is led by the Fellowship Program Advisory Committee.
Awarded fellows are matched with IPC Board Members or Councilors to observe and participate in clinical practice or research involving patients with psoriasis. Fellows gain hands-on experience in real-world settings, whether through investigating, diagnosing, and managing psoriasis in clinical practice, or participating in active research projects in the lab or clinic. In addition, the program fosters lasting professional relationships by engaging fellows in IPC activities and connecting them with global leaders in the field throughout the fellowship year.
The 2026 IPC International Fellowship Program is supported in part by: Johnson & Johnson
IPC Councilor Helen Young provides commentary on a study identifying skin-derived myeloid precursors and CD200+ fibroblasts as key drivers of psoriatic disease spread from the skin to joints, highlighting the CD200–CD200R1 axis as a promising therapeutic target.
IPC Fellow Dr. Yemsrach Abawaji shares her firsthand perspective on the barriers to psoriasis diagnosis and treatment in Ethiopia and opportunities to improve care.
Did you miss the IPC symposium at the 83rd Society for Investigative Dermatology (SID) Annual Meeting? Select session videos are now available. The Arc of Disease Control in Psoriasis: Early Interception – Deep Pathway Blockade – Treatment Failure covered early intervention strategies, treatment selection, immune pathway targeting, PsA prevention, clinical escape, and real-world cases that inform long-term psoriasis care.
Depression affects approximately 20% of patients with psoriasis, five times the rate seen in the general population. IPC Jr. Councilor Mio Nakamura, MD, MS, FAAD, walks through the bidirectional relationship between psoriasis and depression, the shared inflammatory pathways driving both conditions, and practical guidance on screening and incorporating multidisciplinary mental health support into psoriasis management.
